Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armon Sharei

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Small (Weinheim an Der Bergstrasse, Germany)|September 6, 2016
A Size-Selective Intracellular Delivery PlatformMay Tun Saung, Armon Sharei, Viktor A Adalsteinsson, et al.
ACS Chemical Biology|November 1, 2017
Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary CellsJing Li, Bu Wang, Brian M Juba, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2018
Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivoTia DiTommaso, Julie M Cole, Luke Cassereau, et al.
Plos One|April 16, 2015
Ex vivo cytosolic delivery of functional macromolecules to immune cellsArmon Sharei, Radiana Trifonova, Siddharth Jhunjhunwala, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2013
A vector-free microfluidic platform for intracellular deliveryArmon Sharei, Janet Zoldan, Andrea Adamo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in WomenMorgane Griesbeck, Susanne Ziegler, Sophie Laffont, et al.
Investigational New Drugs|March 3, 2023
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumorsAntonio Jimeno, Joaquina Baranda, Wade T Iams, et al.
Frontiers in Immunology|October 20, 2022
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in miceKatarina Blagovic, Carolyne K Smith, Amritha Ramakrishnan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8<sup>+</sup> T Cell Responses with Antitumor ActivityMatthew G Booty, Kelan A Hlavaty, Adam Stockmann, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Small (Weinheim an Der Bergstrasse, Germany)|September 6, 2016
A Size-Selective Intracellular Delivery PlatformMay Tun Saung, Armon Sharei, Viktor A Adalsteinsson, et al.
ACS Chemical Biology|November 1, 2017
Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary CellsJing Li, Bu Wang, Brian M Juba, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2018
Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivoTia DiTommaso, Julie M Cole, Luke Cassereau, et al.
Plos One|April 16, 2015
Ex vivo cytosolic delivery of functional macromolecules to immune cellsArmon Sharei, Radiana Trifonova, Siddharth Jhunjhunwala, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2013
A vector-free microfluidic platform for intracellular deliveryArmon Sharei, Janet Zoldan, Andrea Adamo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2015
Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in WomenMorgane Griesbeck, Susanne Ziegler, Sophie Laffont, et al.
Investigational New Drugs|March 3, 2023
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumorsAntonio Jimeno, Joaquina Baranda, Wade T Iams, et al.
Frontiers in Immunology|October 20, 2022
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in miceKatarina Blagovic, Carolyne K Smith, Amritha Ramakrishnan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 29, 2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8<sup>+</sup> T Cell Responses with Antitumor ActivityMatthew G Booty, Kelan A Hlavaty, Adam Stockmann, et al.
Pageof 2